|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
beta-Naphthylamine |
CAS 91-59-8 | ||
C10H7NH2 |
RTECS QM2100000 | ||
|
Synonyms & Trade Names 2-Aminonaphthalene, 2-Naphthylamine |
DOT ID & Guide 1650 153 |
||
Exposure
|
NIOSH REL: Ca See Appendix A | ||
| OSHA PEL: [1910.1009] See Appendix B | |||
| IDLH Ca [N.D.] See: IDLH INDEX | Conversion | ||
|
Physical Description Odorless, white to red crystals with a faint, aromatic odor. [Note: Darkens in air to a reddish-purple color.] |
|||
|
MW: 143.2 |
BP: 583°F |
MLT: 232°F |
Sol: Miscible in hot water |
|
VP(226°F): 1 mmHg |
IP: 9.71 eV |
|
Sp.Gr(208°F): 1.06 |
|
Fl.P: 315°F |
UEL: ? |
LEL: ? |
|
| Combustible Solid | |||
|
Incompatibilities & Reactivities None reported |
|||
|
Measurement Methods NIOSH 5518; OSHA 93 See: NMAM or OSHA Methods |
|
Personal Protection & Sanitation (See protection) Skin: Prevent skin contact Eyes: Prevent eye contact Wash skin: When contaminated/Daily Remove: When wet or contaminated Change: Daily Provide: Eyewash, Quick drench |
First Aid (See procedures) Eye: Irrigate immediately Skin: Soap wash immediately Breathing: Respiratory support Swallow: Medical attention immediately |
|
Important additional information about respirator selection Respirator Recommendations (See Appendix E) NIOSH At concentrations above the NIOSH REL, or where there is no REL, at any detectable concentration: (APF = 10,000) Any self-contained breathing apparatus that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode (APF = 10,000) Any supplied-air respirator that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode in combination with an auxiliary self-contained positive-pressure breathing apparatus Escape: (APF = 50) Any air-purifying, full-facepiece respirator with an N100, R100, or P100 filter. Click here for information on selection of N, R, or P filters./Any appropriate escape-type, self-contained breathing apparatus |
|
| Exposure Routes inhalation, skin absorption, ingestion, skin and/or eye contact | |
| Symptoms Dermatitis; hemorrhagic cystitis; dyspnea (breathing difficulty); ataxia; methemoglobinemia, hematuria (blood in the urine); dysuria; [potential occupational carcinogen] | |
|
Target Organs
Bladder, skin Cancer Site [bladder cancer] |
|
| See also: INTRODUCTION See MEDICAL TESTS: 0154 |